Alzheimer’s Disease/Dementia News

Eisai and Biogen have submitted a supplemental biologics license application to the FDA for monthly IV maintenance dosing of Leqembi to treat Alzheimer’s disease in patients with mild cognitive impairment or mild dementia.

IGC Pharma has announced positive interim results from an ongoing phase 2 trial investigating IGC-AD1, a natural THC-based oral formulation, as a treatment for agitation in dementia from Alzheimer’s disease.

Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic portfolio featuring a novel, investigational muscarinic antipsychotic to treat schizophrenia and Alzheimer’s disease.

CuraSen Therapeutics has announced positive data from a phase 2a study of its combination adrenergic activator, CST-2032/CST-107, for patients with mild cognitive impairment or mild dementia from Alzheimer’s or Parkinson’s disease.

WEST PALM BEACH, Fla. — Variability and length of pauses in speech may indicate cognitive impairment for German-speaking individuals with multiple sclerosis, according to a poster from ACTRIMS 2024.

The FDA will convene an advisory committee meeting to discuss the safety and efficacy of donanemab in early symptomatic Alzheimer's disease, according to the manufacturer.

The FDA has granted breakthrough device designation to a phospho-tau 217 blood-based biomarker to assist in the diagnosis of Alzheimer’s disease, according to the manufacturer.

Quanterix Corp. has announced collaborations with several health systems with the goal of improving and simplifying Alzheimer’s disease diagnosis by expanding access to blood biomarker assays.

Researchers reported that a population-based study shows statin use among older adults with heart failure was associated with a 20% lower risk for all-cause dementia, including a 28% reduction in risk for developing Alzheimer’s disease.

Otsuka has announced that a phase 3 clinical trial of AVP-786, a combination therapy to treat agitation associated with dementia due to Alzheimer’s disease, failed to achieve its primary endpoints.